These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3932228)

  • 1. Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N).
    Neugebauer G; Betzien G; Hrstka V; Kaufmann B; von Möllendorff E; Abshagen U
    Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):453-60. PubMed ID: 3932228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability and pharmacodynamics of a sustained-release glibenclamide product (Deroctyl) in comparison to a standard tablet formulation (Euglucon, Daonil).
    Ayanoglu G; Witte PU; Badian M
    Int J Clin Pharmacol Ther Toxicol; 1983 Sep; 21(9):479-82. PubMed ID: 6414955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of glibenclamide: a single dose comparison of four preparations in human volunteers.
    Karttunen P; Uusitupa M; Nykänen S; Robinson JD; Sipilä J
    Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):642-6. PubMed ID: 3937815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)].
    Haupt E; Putschky F; Zoltobrocki M; Schöffling K
    Dtsch Med Wochenschr; 1984 Feb; 109(6):210-3. PubMed ID: 6421561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide.
    Chalk JB; Patterson M; Smith MT; Eadie MJ
    Eur J Clin Pharmacol; 1986; 31(2):177-82. PubMed ID: 3100314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New guidelines for the assessment of bioavailability and bioequivalence].
    Blume H; Schug B; Tautz J; Erb K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):548-55. PubMed ID: 15887065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide.
    el-Sayed YM; Suleiman MS; Hasan MM; Abdel-Hamid ME; Najib NM; Sallam ES; Shubair MS
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):551-7. PubMed ID: 2515159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Special pharmacology of the new sulfonylurea glimepiride.
    Geisen K
    Arzneimittelforschung; 1988 Aug; 38(8):1120-30. PubMed ID: 2904269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and effects of glibenclamide in two formulations, HB 419 and HB 420, in type 2 diabetes.
    Arnqvist HJ; Karlberg BE; Melander A
    Ann Clin Res; 1983; 15 Suppl 37():21-5. PubMed ID: 6433769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence and pharmacodynamics of a modified glibenclamide formulation in healthy volunteers.
    Molz KH; Klimmek R; Dilger C; Pabst G; Weber W; Müller M; Jaeger H
    Arzneimittelforschung; 1989 Oct; 39(10):1280-2. PubMed ID: 2514694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bio-availability of three formulations of glibenclamide.
    Meyer BH; Müller FO; Luus HG; Eckert HG
    S Afr Med J; 1989 Aug; 76(4):146-7. PubMed ID: 2503895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and bioequivalence of different formulations of pirenzepine.
    Vergin H; Mascher H; Strobel K; Nitsche V
    Arzneimittelforschung; 1986 Sep; 36(9):1409-12. PubMed ID: 3790194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations.
    Neuvonen PJ; Kivistö KT
    Br J Clin Pharmacol; 1991 Aug; 32(2):215-20. PubMed ID: 1931470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pirprofen on glibenclamide kinetics and response.
    Morrison PJ; Rogers HJ; Spector RG; Bradbrook ID; John VA
    Br J Clin Pharmacol; 1982 Jul; 14(1):123-6. PubMed ID: 6809024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay.
    Rogers HJ; Spector RG; Morrison PJ; Bradbrook ID
    Diabetologia; 1982 Jul; 23(1):37-40. PubMed ID: 6811355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The pharmacokinetics and bioequivalence of various dosage forms of ambroxol].
    Vergin H; Bishop-Freudling GB; Miczka M; Nitsche V; Strobel K; Matzkies F
    Arzneimittelforschung; 1985; 35(10):1591-5. PubMed ID: 4074420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefetamet pivoxil clinical pharmacokinetics.
    Blouin RA; Stoeckel K
    Clin Pharmacokinet; 1993 Sep; 25(3):172-88. PubMed ID: 8222459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hydroxylation of glibenclamide by liver biopsy specimens].
    Glogner P; Heni N
    Arzneimittelforschung; 1975 Jun; 25(6):860-1. PubMed ID: 809044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.